Targeted new cancer drugs, designed at unprecedented scale

We revolutionise the discovery and development of bispecific antibody drug conjugates (bsADCs) to find the right treatment for any type of cancer.

Get in Touch
A downwards-pointing arrow

Our Solution

The next generation of ADC development

Bispecific ADCs (bsADCs) have the potential to revolutionise ADCs as dual targeting enables improved function and cell selectivity. Our technology allows us to quickly design and test new bsADCs with complex structures and diverse target and payload combinations.

a right-pointing arrow
Learn More About Our Technology

Rapid Design

The discovery of bsADCs is held back by an inability to rapidly generate and screen new therapeutic candidates. Valink can build thousands of drug candidates in days
from a variety of components, including antibody fragments and small molecules.

Novel Drug Candidates

Using our LiliumX™ discovery platform, we solve the fundamental challenges of bsADC discovery. This allows us to unlock unprecedented therapies in solid tumours
and beyond.

More Effective Treatments

We target solid tumours with bispecific antibody-drug conjugates. By aiming at two markers at once, we can improve payload delivery and more accurately differentiate between malignant and healthy tissues.

Noteworthy

Latest News

a right-pointing arrow
See More Stories

Backed By:

Contact Us

United States

Valink Therapeutics Inc
50 Milk Street,
16th floor,
Boston,
MA 02109

United Kingdom

Valink Therapeutics Ltd
Imperial I-Hub,
84 Wood Lane,
London,
W12 0BZ

a tick

Message sent successfully.

a cross

Oops, something happened. Please try again.

United Kingdom

Valink Therapeutics Ltd
Imperial I-Hub,
84 Wood Lane,
London,
W12 0BZ
United States

Valink Therapeutics Inc
50 Milk St.,
16th floor,
Boston,
MA 02109